Item 8.01 Other Events.
As previously reported, on April 11, 2023, Satsuma Pharmaceuticals, Inc. (the
"Company") received a written notice from the staff (the "Staff") of the Listing
Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), notifying the
Company that, for the 30 consecutive business day period between February 27,
2023 through April 10, 2023, the Company's common stock, $0.0001 par value per
share (the "Common Stock"), had not maintained a minimum bid price of $1.00 per
share, required for continued listing on the Nasdaq Global Market pursuant to
Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The letter
also indicated that the Company had a compliance period of 180 calendar days, or
until October 8, 2023, in which to regain compliance pursuant to Nasdaq Listing
Rule 5810(c)(3)(A). The letter further provided that if, at any time during the
180-day period, the closing bid price of the Company's common stock was at least
$1.00 for a minimum of 10 consecutive business days, the Staff would provide the
Company with written confirmation that it had achieved compliance with the
Minimum Bid Price Requirement.
On May 1, 2023, the Company received a letter from the Staff notifying the
Company that for the last 10 consecutive business days, from April 17, 2023 to
April 28, 2023, the closing bid price of the Company's common stock has been at
$1.00 per share or greater and, therefore, the Company has regained compliance
with Nasdaq Listing Rule 5450(a)(1) and this matter is now closed.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
SATSUMA PHARMACEUTICALS, INC. 
